Introduction
============

The coronaviruses (CoVs) are a diverse family of enveloped, positive-sense RNA viruses that are distributed widely among animal species. The recent emergence of a novel human CoV responsible for severe acute respiratory syndrome (SARS) ([@bib13], [@bib32], [@bib33], [@bib45]) highlights the public health risks associated with the continual evolution and zoonotic spread of new CoVs. The human SARS-CoV of 2002--2003 was likely derived from a CoV of the civet cat, an animal common to live-animal food markets in China ([@bib23]). Cross-species transmission events have also been implicated in the emergence and establishment of other novel CoVs, such as the transmissible gastroenteritis virus (TGEV) of pigs ([@bib48]) and the human respiratory CoV OC43 ([@bib59]).

The spike (S) glycoprotein of the CoV is an important determinant of virus host range and pathogenicity ([@bib35]). This glycoprotein mediates the initial attachment of the virus to host-cell receptors and the subsequent fusion of the viral and cellular membranes to allow entry of the virion core. The S glycoproteins within the CoV family differ among themselves in several features that are reflective of their serologic and phylogenetic groupings ([@bib21], [@bib35]). Of particular interest is the dimorphism seen with respect to proteolytic maturation of the S glycoprotein precursor. In the group 2 viruses, such as the prototype murine hepatitis virus (MHV), and in the avian group 3 viruses, the S glycoprotein precursor is cleaved, likely by furin-like cellular proteases ([@bib12]), to yield the canonical receptor-binding (S1) and transmembrane fusion (S2) subunits. By contrast, the S glycoproteins of the group 1 viruses are not subjected to proteolytic cleavage during biogenesis. Interestingly, the newly emerged SARS-CoV displays characteristics of both groups: although the SARS-CoV is phylogenetically related to the group 2 viruses ([@bib19], [@bib53]), the S glycoprotein does not show evidence of proteolytic maturation ([@bib41], [@bib50], [@bib54], [@bib62]).

The absence of proteolytic cleavage in certain S glycoproteins stands in contradistinction to the special role for proteolytic maturation in the structure and function of other Class I viral envelope glycoproteins. Cleavage by cellular proteases is universally required to enable the fusion potential of the envelope glycoproteins of retroviruses, orthomyxoviruses, paramyxoviruses, filoviruses and arenaviruses. Upon subsequent activation of the matured Class I envelope glycoprotein, by receptor binding and/or low endosomal pH, these complexes undergo profound structural reorganization to ultimately form highly stable trimer-of-hairpins structures that contribute to fusion of the viral and cellular membranes (([@bib15], [@bib28], [@bib52], [@bib60]) and references therein). Although the SARS-CoV S glycoprotein is a bona fide member of the Class I fusion proteins ([@bib7], [@bib14], [@bib16], [@bib57], [@bib63]), it paradoxically appears able to initiate membrane fusion without proteolytic activation and to complete the conformational changes without proteolytic separation of the S1 and S2 subunits.

The requirement for proteolytic maturation among the normally cleaved S glycoproteins of the group 2 CoV species is likewise ambiguous. In the MHV glycoprotein, mutations that alter the furin protease recognition sequence (R-X-R/K-R↓; ([@bib40], [@bib47]) and references therein) and prevent cleavage generally diminish cell--cell fusion activity ([@bib5], [@bib12], [@bib56], [@bib58], [@bib64]), yet do not markedly affect viral infectivity or pathogenesis ([@bib6], [@bib12], [@bib25]). By contrast, MHV infectivity can be enhanced by exogenous treatment with trypsin ([@bib56]), raising the possibility that proteases that recognize single basic residues may be important. Thus, the role of proteolytic maturation in CoV entry, and the identity of the putative cellular protease, remains unclear.

In this report, we examined the effect of proteolytic cleavage on the ability of the SARS-CoV S glycoprotein to mediate cell--cell fusion and viral infectivity. We show that the introduction of a prototypic furin recognition motif at R667 allows for efficient cleavage of the mutant glycoprotein and increased cell--cell fusion activity. Nonetheless, the cleaved S glycoprotein was not able to enhance the infectivity of pseudotyped virions. These findings reinforce, in the converse, the observations reported in the naturally cleaved group 2 CoVs ([@bib6], [@bib12], [@bib25]) and call attention to the distinct, albeit unclear, requirements for virion entry in the CoVs.

Results
=======

Sequence analysis of CoV S glycoproteins
----------------------------------------

The amino acid sequence of the SARS-CoV S glycoprotein was compared with that of representative CoVs of group 1 (HuCoV-229E, HuCoV-NL63, TGEV and FIPV) and group 2 (HuCoV OC43, MHV and BCoV) using the MAXHOM algorithm ([@bib49]). Alignment within the S1 receptor-binding domain was minimal, and meaningful similarity was observed only in the S2 fusion domain. These similarities include the N- and C-terminal heptad-repeat regions that together comprise the α-helical core of the fusion-active trimer-of-hairpins structure and the intervening 'loop' region. Extending towards the N-terminus, the alignment could readily be followed through to a well-conserved nonamer (IPTNFSISI) at SARS-CoV positions 696--704 ([Fig. 1](#fig1){ref-type="fig"}A). In the group 2 viruses that are proteolytically cleaved (e.g., MHV and BCoV), the furin protease recognition site lies 33 amino acids upstream of this nonamer (RRAHR and RRSRR, respectively). The HuCoV OC43 contains a variant site (RRSRG) at which cleavage may also occur ([@bib34]). Further upstream of the furin-like recognition site in the group 2 glycoproteins, we identified a GxCx motif that could also be made to align with the group 1 and SARS-CoV glycoproteins ([Fig. 1](#fig1){ref-type="fig"}A). We speculate that the conserved GxCx and nonamer motifs delineate the junction between the S1 and S2 domains in the SARS-CoV S glycoprotein.Fig. 1Sequence alignment to define the putative S1--S2 junctional region of SARS-CoV S glycoprotein. (A) The MAXHOM algorithm ([@bib49]) as accessed in the PredictProtein suite ([http://cubic.bioc.columbia.edu/predictprotein](http://www.cubic.bioc.columbia.edu/predictprotein)) was used for the initial alignment of the full-length amino acid sequences of the following CoV S glycoproteins: SARS-CoV (Urbani; AAP1344), murine hepatitis virus (MHV; AAA87062), bovine CoV (BCoV; AAF25499), human respiratory CoV OC43 (AAT84362), feline infectious peritonitis virus (FIPV; VGIH79), porcine transmissible gastroenteritis virus (TGEV; AAT00645) and the human respiratory CoVs 229E (AAK32191) and NL63 (AAS58177). The regions containing the furin cleavage site (in group 2 viruses; underlined) and the S1 GxCx motif and conserved S2 nonamer (gray) were manually adjusted to yield the alignment shown. A tyrosine (Y) present in all S1 domains is also underlined. Deletions in SARS-CoV and the group 1 viruses (.) are arbitrarily displayed. (B) The two basic residues in the junctional region of the wild-type SARS-CoV S glycoprotein (R667 and K672) are indicated by diamonds. The furin protease recognition sites engineered at these sites are underlined in the HTR, HTVR and SLLR mutants.

We find considerable sequence variation and deletion between the GxCx motif and the conserved S2 nonamer in the uncleaved group 1 CoV S glycoproteins. In FIPV and TGEV, the deletions remove all basic amino acids that might be used in furin- or trypsin-mediated cleavage. By contrast, one or more basic residues remain in the glycoproteins of SARS-CoV and the human CoVs 229E and NL63. The alignment for these human viruses in [Fig. 1](#fig1){ref-type="fig"}B highlights the single arginine at position 667 of the SARS-CoV S glycoprotein, which may signal a protease-sensitive site. Another basic residue in this region of the SARS-CoV glycoprotein (lysine 672) may likewise be relevant to protease recognition.

Mutation at R667, but not K672, affects S-glycoprotein-mediated cell--cell fusion
---------------------------------------------------------------------------------

Although biochemical evidence for proteolytic cleavage in the wild-type SARS-CoV glycoprotein is largely negative ([@bib41], [@bib50], [@bib54], [@bib62]), we cannot exclude the possibility that trace levels of cleavage by proteases that recognize single (trypsin-like) or multiple (furin-like) basic residues may in fact be responsible for S-glycoprotein-mediated membrane fusion. To test this hypothesis, we mutated the two basic amino acids in the presumptive S1--S2 junction region to serine. As shown in [Fig. 2](#fig2){ref-type="fig"}A (top), the wild-type, R667S and K672S glycoproteins were comparably expressed to yield the intact S glycoprotein, which migrated as two precursor bands: the mature, terminally glycosylated form of 220 kDa molecular weight (*S* ~r~) and an Endo H-sensitive (*S* ~s~) form of 200 kDa (([@bib54]) and K.E.F. and J.H.N, unpublished). These collapse upon deglycosylation with PNGase F to yield the 140 kDa S polypeptide ([Fig. 2](#fig2){ref-type="fig"}A, bottom). The R667S and K672S mutations did not appear to alter the expression or glycosylation of the glycoproteins, and we too find no evidence of proteolytic cleavage to form S1 and S2 subunits. Interestingly, however, the ability of the R667S mutant to promote cell--cell fusion was consistently reduced to 60% of wild-type levels ([Fig. 2](#fig2){ref-type="fig"}B). Fusion by the K672S mutant was largely unaffected. These results point to R667 as an important amino acid in the S glycoprotein and perhaps as a site susceptible to proteolytic cleavage.Fig. 2Serine mutation at R667, but not K672, reduces the ability of the S glycoprotein to mediate cell--cell fusion. (A) Wild-type SARS-CoV S glycoprotein and the R667S and K672S mutants were metabolically labeled in COS-7 cells and isolated using the C-terminal S-peptide (Spep) affinity tag ([@bib29]). The mock lane represents cells transfected without vTF7-3 infection. Proteins were resolved by SDS polyacrylamide gel electrophoresis in NuPAGE 3--8% Tris--acetate gels (Invitrogen) either as the isolated glycoproteins (above) or following deglycosylation using PNGase F (below). The Endo-H-resistant (*S*~r~) and Endo-H-sensitive (*S*~s~) forms of the S glycoprotein are indicated, as is the fully deglycosylated S polypeptide (S). \[^14^C\]-methylated Rainbow molecular weight markers are indicated. The images are printed dark to highlight the absence of proteolytic cleavage. (B) The ability of the S glycoproteins to promote ACE2-dependent cell--cell fusion was detected using the recombinant vaccinia virus-based β-galactosidase reporter assay ([@bib44], [@bib66]). COS-7 cells expressing the wild-type and mutant glycoproteins were co-cultured with COS-7 cells transiently expressing the SARS-CoV cellular receptor ACE2 and infected with the fusion reporter recombinant vaccinia virus vCB21R-lacZ ([@bib44], [@bib66]). X-gal was used to detect β-galactosidase activity arising from cell--cell fusion. The number of blue syncytia is shown from two experiments, and error bars represent one standard deviation. Transfection efficiencies were comparable in all cases.

Insertion of furin recognition sites in the SARS-CoV S glycoprotein
-------------------------------------------------------------------

To investigate whether proteolytic cleavage at the basic amino acid residues, were it to occur, might facilitate cell--cell fusion activity, we mutated the wild-type SARS-CoV glycoprotein to construct a prototypic furin recognition site (RRSRR) at either position. Based on our alignment, we engineered three variants ([Fig. 1](#fig1){ref-type="fig"}B): one at position R667 to replace the resident sequence with YHTRRSRR (referred to as HTR) and another at the same position designed to accommodate the deletion indicated in the alignment, YHTVRRSRR (HTVR). The sequence at K672 (RSTSQK) was shortened to RRSRR in order to include the two naturally occurring basic residues (the SLLR variant). These furin-site-containing glycoproteins were expressed in COS-7 cells and isolated using the C-terminal affinity tag ([Fig. 3](#fig3){ref-type="fig"}). Proteolytic cleavage to yield novel subunits of 110 kDa and 90 kDa was apparent in the HTVR glycoprotein and less so in HTR (top left). Little cleavage was seen in the SLLR glycoprotein. The proteolytically cleaved products appear to be derived from the mature, terminally glycosylated *S* ~r~ form of the S glycoprotein as the 220 kDa form in HTVR was consistently reduced relative to the *S* ~s~ form. This result is in keeping with the subcellular localization of the furin protease in the *trans*-Golgi network ([@bib40], [@bib47]). Upon deglycosylation with PNGase F, the two novel subunits in HTVR and HTR migrated as 72 and 64 kDa peptides (bottom, left), consistent with the anticipated molecular weights of the predicted S1 and S2 polypeptides, respectively. The S2 polypeptide was typically accompanied by lower molecular forms, which suggest additional N-terminal cleavage events. As in the naturally cleaved S glycoprotein of MHV ([@bib31]), the S1 and S2 subunits derived from the furin-site-containing glycoproteins remain associated upon cell lysis in nonionic detergent.

The virus-neutralizing S-glycoprotein-specific monoclonal antibody (MAb) F26G18 ([@bib3]) recognizes a predominantly linear epitope in the S1 subunit of the SARS-CoV S glycoprotein (unpublished). This enabled us to determine whether the S1 subunit was shed from the proteolytically cleaved complex, as has been reported for the naturally cleaved MHV S glycoprotein ([@bib31]). Upon immunoprecipitation from the medium ([Fig. 3](#fig3){ref-type="fig"} ; right), the S1 subunit was readily isolated in cultures expressing HTVR and HTR. A small amount of S1 was also shed from the SLLR mutant. No S1 subunit was found in the culture medium from cells expressing the wild-type SARS-CoV S glycoprotein, consistent with the lack of proteolytic cleavage. Taken together, these studies indicate that proteolytic cleavage of the SARS-CoV S glycoprotein can be achieved by the introduction of a furin recognition motif, especially at R667. The differences in the degree of cleavage between the two R667 mutants, and in SLLR, suggest specificity in the recognition of the engineered furin sites.Fig. 3Proteolytic cleavage of the S glycoprotein at introduced furin sites. Wild-type S glycoprotein and the furin-site-containing mutants HTVR, HTR and SSLR were metabolically labeled in COS-7 cells. The S glycoprotein in cell lysates was affinity isolated (cells; left panels), whereas the S1 subunit in the cell culture supernatant (medium; right panels) was immunoprecipitated using MAb F26G18 ([@bib3]). Polypeptides obtained upon deglycosylation with PNGase F are shown in bottom panels. Molecular weight markers and S glycoforms are as described in [Fig. 2](#fig2){ref-type="fig"}A. Both S1 and S2 polypeptide molecular weights are consistent with cleavage in the junctional region.

HTVR is transported to the cell surface as the wild-type glycoprotein
---------------------------------------------------------------------

Based on our observation that the S1 subunit is shed from cells expressing the furin-site-containing glycoproteins, we investigated the expression and receptor-binding capability of the complex on the cell surface. COS-7 cells transiently expressing the wild-type and HTVR glycoproteins were stained to detect the S1 domain using MAb F26G18 ([@bib3]). Upon flow cytometric analysis ([Fig. 4](#fig4){ref-type="fig"} ), the population of positively staining cells was comparable in number and fluorescence intensity in both the wild-type and HTVR mutant, suggesting comparable transport and cell-surface expression of the two glycoproteins. Studies using recombinant soluble ACE2 ([Fig. 4](#fig4){ref-type="fig"}) failed to demonstrate significant differences in the capacity of the cell-surface glycoproteins to bind receptor.Fig. 4Flow cytometric analysis of cell surface S glycoprotein. COS-7 cells transiently expressing the wild-type and HTVR mutant S glycoproteins were stained using either (top) MAb F26G18 ([@bib3]) and a secondary fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibody or (bottom) a recombinant soluble ACE2 receptor, biotinylated goat anti-ACE2 antibody and FITC-conjugated streptavidin. Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences), and propidium-iodide-staining (dead) cells were excluded. Background staining of mock-transfected cells is shown in the left panel; non-expressing cells are also evident in the transfected cell populations. Expressing cells were defined using a gate of ≥30 (\<0.1% of the mock-transfected population).

Membrane fusion activity of the furin-site-containing mutant glycoproteins
--------------------------------------------------------------------------

We then investigated the consequences of proteolytic cleavage on the ability of the SARS-CoV S glycoprotein to mediate membrane fusion. As shown in [Fig. 5](#fig5){ref-type="fig"} , COS-7 cells expressing the HTVR glycoprotein were markedly enhanced in their ability to fuse with cells expressing the ACE2 receptor. In multiple experiments, this mutant generated 3- to 8-fold more syncytia than did the wild-type S glycoprotein. The HTR glycoprotein was also more fusogenic than the wild-type (1.8 fold), whereas the insertion in SLLR appeared to inhibit fusion. Discounting potential detrimental effects of the amino acid substitutions per se, the fusogenicity of the mutant glycoproteins generally correlated with the extent of proteolytic cleavage ([Fig. 3](#fig3){ref-type="fig"}). Recombinant expression of ACE2 receptor was required in all cases for fusion. The marked increase in fusogenicity in concert with proteolytic cleavage suggests strongly that proteolytic maturation of the CoV S glycoprotein impacts the ability of the glycoprotein to mediate membrane fusion.Fig. 5Cell--cell fusion is enhanced by proteolytic cleavage. Wild-type S glycoprotein and the furin-site-containing mutants HTVR, HTR and SSLR were expressed in COS-7 cells, and fusogenicity was determined as described in [Fig. 2](#fig2){ref-type="fig"}B ([@bib44], [@bib66]). The number of blue syncytia relative to that in the wild-type S glycoprotein control is shown from four independent experiments, and error bars represent one standard deviation. Transfection efficiencies within each experiment were comparable.

Proteolytic cleavage of the mutant glycoproteins is mediated by furin protease
------------------------------------------------------------------------------

We further investigated our assumption that proteolytic cleavage in the furin-site-containing mutants is mediated by the furin protease, and not by adventitious cellular enzymes that may also cleave at the highly hydrophilic furin recognition site. A Chinese hamster ovary (CHO) cell line deficient in furin protease (FD11; ([@bib22])) was obtained from S. Leppla (NIH) and used to express the S glycoproteins. The FD11 cell line was derived following chemical mutagenesis and selection for resistance to anthrax toxin protective antigen (PA), which is activated intracellularly by furin cleavage ([@bib22]). As shown in [Fig. 6](#fig6){ref-type="fig"} , proteolytic processing of the HTVR, HTR and SLLR glycoproteins was abrogated in the furin-deficient FD11 cell line. The S1 and S2 subunits were absent in FD11 cells, and S1 was not detected in the cell culture medium. These findings provide evidence that proteolytic cleavage in the furin-site-containing mutants is indeed mediated by the furin protease.Fig. 6Proteolytic processing in furin-deficient FD11 and wild-type CHO cells. Wild-type S glycoprotein and the furin-site-containing mutants HTVR, HTR and SSLR were metabolically labeled in furin-deficient cells and parental CHO cells ([@bib22]). The S glycoprotein in cell lysates was affinity isolated (top panels), and the S1 subunit in the cell culture medium (bottom panels) was immunoprecipitated using MAb F26G18 ([@bib3]).

Efforts to determine the relative fusogenicity of the cleaved and uncleaved glycoproteins in the CHO and FD11 cells were confounded, however, by differences in the levels of S glycoprotein expression. Although cell--cell fusion by both the wild-type and HTVR glycoproteins was dramatically reduced in furin-deficient FD11 cells ([Fig. 7](#fig7){ref-type="fig"}B), the relative transfection efficiencies in the two cell lines also differed markedly (4% vs. 20% in the parental CHO cells). The basis for this difference is unclear and was not mitigated in a furin-expressing cell line derived from FD11 ([@bib22]). Direct comparison of fusion activity in the two cell lines was therefore difficult.Fig. 7Co-expression of furin cDNA enhances proteolytic cleavage and cell--cell fusion. (A) Wild-type or HTVR S glycoprotein plasmid was co-transfected with a furin-expressing plasmid (+furin cDNA), or a pcDNA3.1^−^ control (−furin cDNA), into furin-deficient FD11 or wild-type CHO cells ([@bib22]). The S glycoproteins were expressed and metabolically labeled as described in [Fig. 3](#fig3){ref-type="fig"}. Isolated glycoproteins from cell lysates (top panel) were also examined following deglycosylation with PNGase F (middle panel); shed S1 subunit was immunoprecipitated from the cell culture medium and examined following deglycosylation (bottom panel). Molecular weight markers and forms of the S glycoprotein are as described in [Fig. 3](#fig3){ref-type="fig"}. A 69 kDa molecular weight form of S1 was also detected in the culture medium upon PNGase F-treatment (indicated by \*), as was a 140 kDa polypeptide which is consistent with blebbing of the intact S glycoprotein. (B) Cell--cell fusion was assessed using the indicated S-glycoprotein-expressing cells and COS-7 target cells expressing exogenous ACE2 receptor. The number of blue syncytia is shown from two experiments, and error bars represent one standard deviation. Small error bars are not shown.

To circumvent this problem, we co-expressed the S glycoprotein with furin cDNA in FD11 cells. As anticipated, recombinant furin expression was required for proteolytic cleavage of the HTVR glycoprotein in FD11 cells ([Fig. 7](#fig7){ref-type="fig"}A). Despite the reduced levels of S glycoprotein expression in the FD11 cells, S1 and S2 subunits were generated and S1 glycoprotein was shed into the culture medium with good efficiency. Cell--cell fusion by the HTVR glycoprotein was also enhanced by co-expression of furin in FD11 cells ([Fig. 7](#fig7){ref-type="fig"}B). Interestingly, the wild-type S glycoprotein was also cleaved in CHO cells co-expressing the furin cDNA to yield S1 and S2 subunits that co-migrated with those in the HTVR glycoprotein ([Fig. 7](#fig7){ref-type="fig"}A). This may represent exuberant cleavage at the suboptimal SLLR~667~ site in the wild-type glycoprotein. Concomitant with this cleavage event, cell--cell fusion by the wild-type S glycoprotein was enhanced by co-expression of furin ([Fig. 7](#fig7){ref-type="fig"}B). In addition to the nominal S1 subunit, these cells also shed a larger glycoprotein (indicated by the asterisk in [Fig. 7](#fig7){ref-type="fig"}A) whose molecular weight is consistent with cleavage at a previously suggested furin recognition motif at position 758--761 (RNTR ([@bib62])), a site we place by sequence alignment in the S2 subunit ([Fig. 1](#fig1){ref-type="fig"}A).

The dramatic effects observed upon co-expression of furin in an experimental setting raise the possibility of cryptic cleavage events in the wild-type S glycoprotein under natural conditions. The ability of the co-expressed furin to cleave the wild-type glycoprotein to produce S1 and S2 subunits that co-migrate with those generated in the HTVR mutant lends credence to the suggestion that the S1--S2 junctional region defined by sequence alignment ([Fig. 1](#fig1){ref-type="fig"}) may contain vestigial or inefficiently utilized furin recognition sites.

R667 is important for furin-mediated cleavage in the wild-type S glycoprotein
-----------------------------------------------------------------------------

To specifically determine which of the basic residues within the junctional region is utilized for cleavage of the wild-type S glycoprotein, we re-examined the expression of the R667S and K672S mutant glycoproteins in CHO cells co-transfected to over-express the furin cDNA. S1 and S2 subunits were generated in cell lysates of both the wild-type and K672S glycoproteins, but not in the R667S mutant. Consistent with this finding, only cells expressing the wild-type and K672S glycoproteins were able to shed S1 glycoprotein to the cell culture medium ([Fig. 8](#fig8){ref-type="fig"}A). These findings suggest that the furin-mediated cleavage event at R667 is disrupted by the substitution of serine and, importantly, is responsible for the generation of the S1 subunit in the wild-type and HTVR glycoproteins. By contrast, the larger S1-like fragment thought to represent cleavage at the RNTR site at position 758--761 (indicated by the asterisk in [Fig. 8](#fig8){ref-type="fig"}A) was produced and shed by both the R667S and K672S mutants and by the wild-type glycoprotein.Fig. 8Co-expression of furin cDNA results in cleavage and enhanced fusogenicity of the wild-type and K672S glycoproteins. (A) Wild-type or mutant S glycoprotein plasmid (R667S or K672S) was co-transfected into wild-type CHO cells with a furin-expressing plasmid (+furin cDNA) or a pcDNA3.1^−^ control (−furin cDNA). Isolated glycoproteins from cell lysates (cells; top panel) and immunoprecipitated S1 subunit from culture medium (bottom panel) were deglycosylation with PNGase F. Molecular weight markers and forms of the S polypeptide, including the larger S1 fragment (\*), are as described in [Fig. 7](#fig7){ref-type="fig"}. The intact S polypeptide present in the medium (bottom panel) is shown for internal size reference. (B) Cell--cell fusion was assessed using the S-glycoprotein-expressing CHO cells and COS-7 target cells expressing exogenous ACE2 receptor. The number of blue syncytia is shown from two experiments, and error bars represent one standard deviation. Smaller error bars are not shown.

We had shown that the membrane fusion activity of the R667S glycoprotein was reduced in COS-7 cells relative to the wild-type glycoprotein ([Fig. 2](#fig2){ref-type="fig"}B), and a similar result was obtained in CHO cells ([Fig. 8](#fig8){ref-type="fig"}B). Co-expression of furin cDNA in the CHO cells resulted in a 5-fold increase in fusion activity by the wild-type and the K672S glycoproteins ([Fig. 8](#fig8){ref-type="fig"}B). The increase was considerably blunted in the R667S mutant, consistent with the reduction in furin-mediated cleavage at the mutated SLLS~667~ site. Thus, maximal cell--cell fusion activity correlates with the presence of the S1 subunit generated by cleavage at R667. The larger S1-like product, generated in all the glycoproteins and thought to reflect cleavage at position 761, is likely not a key contributor to fusion competence.

Enhanced cell--cell fusion activity does not translate to increased virion infectivity
--------------------------------------------------------------------------------------

Studies of the normally cleaved S glycoprotein of group 2 MHVs have highlighted a clear and puzzling distinction between the roles of proteolytic cleavage in cell--cell fusion and in virion infectivity and pathogenicity ([@bib6], [@bib12], [@bib25]). To determine whether proteolytic cleavage of the normally uncleaved SARS-CoV S glycoprotein affects virion infectivity, we generated pseudotyped retroviral virions bearing the wild-type and HTVR SARS-CoV glycoproteins ([@bib41], [@bib50], [@bib65], [@bib67]). For these studies, we utilized the HIV-1 provirus-based vector pNL4-3.Luc.R^−^E^−^, which has been engineered to disrupt HIV envelope glycoprotein expression and to encode a luciferase reporter protein ([@bib11]). A codon-optimized S glycoprotein gene ([@bib41]) was provided by M. Farzan (Harvard Medical School, Boston) to obviate the need for vTF7-3 in these studies. The codon-optimized gene was further modified to delete the C-terminal 19 amino acids (co-S Δ19) that interfere with pseudotyping efficiency ([@bib18], [@bib20], [@bib41]). Purified pseudotyped virions bearing the wild-type co-S Δ19 glycoprotein or the HTVR-derivative were initially examined by immunoprecipitation to characterize pseudotype formation ([Fig. 9](#fig9){ref-type="fig"}A). Comparable levels of HIV Gag proteins p24 and p17 were found in pseudotyped particles bearing either co-S Δ19 or co-HTVR Δ19 glycoproteins. Importantly, comparable amounts of the two S glycoproteins were incorporated into the retroviral particles. Pseudotyped virions containing the HTVR glycoprotein were highly enriched in the cleaved subunits (S1 and S2) relative to the expressing cells (e.g., [Fig. 3](#fig3){ref-type="fig"}), although the uncleaved form was also present. This enrichment is likely due to the exclusion of immature intracellular forms of the glycoprotein from the pseudotyped virion sample. As anticipated, no cleaved S glycoprotein products were observed in virions bearing the wild-type co-S Δ19 glycoprotein. Thus, the respective S glycoproteins are comparably and faithfully incorporated into pseudotyped virions.Fig. 9Pseudotyped virions bearing HTVR S glycoprotein are *not* enhanced in their infectivity. (A) Metabolically labeled pseudotyped virions bearing the co-S Δ19 or co-HTVR Δ19 glycoprotein were pelleted through 20% sucrose and solubilized in 1% Triton X-100 lysis buffer prior to immunoprecipitation. HIV proteins were isolated using anti-HIV immunoglobulin from infected individuals (HIVIG; [@bib46]), and SARS-CoV S glycoproteins were immunoprecipitated using MAb F26G18 ([@bib3]). Particles lacking any envelope glycoprotein (null) served as controls. S-glycoprotein-containing samples were heated to 100 °C prior to SDS-PAGE electrophoresis to disrupt S2 oligomers. Molecular weight markers, HIV proteins (Gag p24 and p17) and forms of the S glycoprotein are indicated. (B) Pseudotyped virions bearing the co-S Δ19 or co-HTVR Δ19 glycoprotein, or the VSV G glycoprotein control, were used to infect 293T cells transiently expressing ACE2 (+) or native 293T cells (−). Fresh pseudotyped virion stocks were applied neat to 293T cell microcultures, and infection was determined 2 days later by chemiluminescence of the luciferase reporter (reported in relative light units (RLUs)). No infection by S-glycoprotein-containing virions was detected (ϕ) in the absence of ACE2 expression. Error bars represent one standard deviation.

To determine the infectivity of the respective pseudotyped virions, cell culture supernatants were incubated with human 293T cells expressing the ACE2 receptor, and viral entry was assessed 2 days later by expression of the luciferase gene reporter. Despite the dramatic differences observed in assays of cell--cell fusion, pseudotyped virions bearing the co-S Δ19 or co-HTVR Δ19 glycoprotein were equally infectious ([Fig. 9](#fig9){ref-type="fig"}B). Expression of the ACE2 receptor remained essential for entry. Thus, the enhanced facility of the furin-cleaved HTVR glycoprotein to mediate membrane fusion is apparently not reflected in the overall process of virion entry. The disconnect between the membrane fusion activity of the S glycoprotein and its ability to mediate viral entry, demonstrated here in the normally uncleaved SARS-CoV S glycoprotein and previously in the normally cleaved glycoprotein of MHV ([@bib6], [@bib12], [@bib25]), highlights unresolved complexities in the pathway used by CoVs to infect target cells.

Discussion
==========

The paradigm developed from the study of other Class I viral fusion proteins -- that proteolytic maturation of a precursor glycoprotein is absolutely required to activate the fusogenic potential of the envelope glycoprotein complex -- is not neatly applied to the CoV S glycoprotein. Some naturally occurring CoV S glycoproteins undergo proteolytic cleavage (those of the group 2 and 3 CoVs) and others do not (those of the group 1 viruses). Judging that it is unlikely that a proteolytically intact S glycoprotein is capable of mediating membrane fusion, one is left to consider the alternative that the fusion activity of the group 1 viruses, and the newly emerged SARS-CoV, may derive from proteolytic cleavage that has heretofore gone undetected. In this report, we have examined the role of furin cleavage on the fusogenicity of the normally uncleaved SARS-CoV S glycoprotein. We found that introduction of a synthetic furin recognition sequence at R667 in the putative S1--S2 junctional region enabled efficient cleavage of the S glycoprotein to generate discrete S1 and S2 subunits and markedly increased the ability of the spike complex to mediate cell--cell fusion. In the wild-type S glycoprotein, over-expression of furin cDNA made manifest a cleavage event that has not been otherwise observed (see also [@bib2]), most likely at the naturally occurring sequence SLLR~667~. This exuberant cleavage likewise resulted in an increase in fusogenicity. Direct physical confirmation of cleavage at R667 is however lacking. Although a synthetic peptide bearing the SLLR site was insensitive to furin cleavage in vitro ([@bib2]), it is possible that this sequence may be recognized under some natural conditions. For instance, cleavage might take place on the extracellular virion, perhaps in specialized tissue environments ([@bib30]) or upon endocytosis ([@bib42], [@bib50], [@bib65]).

In our studies, we show a consistent correlation between furin cleavage at SLLR~667~ and an increased ability of the glycoprotein to mediate cell--cell fusion. By contrast, furin-mediated cleavage of the S glycoprotein at a more C-terminal recognition motif, RNTR~761~, does not appear to affect fusogenicity. Although cleavage at these sites has previously been reported ([@bib2]), our studies demonstrate the importance of the SLLR~667~ cleavage in fusion competence of the S glycoprotein. This finding is in agreement with the evolutionary homology in this S1--S2 junctional region among CoV species ([Fig. 1](#fig1){ref-type="fig"}).

Based on the widespread conservation of furin recognition sites in the group 2 and 3 CoVs, we have focused on this protease. Interestingly, inhibition of furin activity by a peptidic furin inhibitor has recently been reported to prevent the cytopathic effect of SARS-CoV infection in cell culture ([@bib2]). Nonetheless, other proteolytic enzymes have also been implicated in CoV entry ([@bib39], [@bib50], [@bib55], [@bib56]). The recent finding that SARS-CoV entry can be blocked by a specific inhibitor of cathepsin L ([@bib27], [@bib51]) highlights the possible role of endosomal proteases. The multiple opportunities for proteolytic activation of the S glycoprotein in natural infection remain to be examined.

The specific facilitation of cell--cell fusion activity by furin cleavage of the SARS-CoV S glycoprotein reported here extends previous findings from studies of the naturally cleaved group 2 CoVs, in which *reductions* in S glycoprotein cleavage have been associated with *deficiencies* in cell--cell fusion activity ([@bib5], [@bib12], [@bib56], [@bib58], [@bib64]). Despite a reasonable correlation between proteolytic cleavage and membrane fusion activity in both the naturally cleaved and uncleaved S glycoproteins, the presence or absence of furin cleavage appears to have surprisingly little impact on the infectivity of the virion particle. MHV virions that contain significant mutations in the furin-recognition site are not proteolytically cleaved yet remain infectious and pathogenic ([@bib6], [@bib12], [@bib25]). Here, we demonstrate the converse---that pseudotyped virions bearing the cleaved HTVR glycoprotein are no more capable of mediating virion entry than those bearing the uncleaved wild-type S glycoprotein.

The discordant effects of proteolytic cleavage highlight the potential for differences in the requirements and pathways for S-glycoprotein-mediated cell--cell fusion and viral entry. This dichotomy is further reflected in the ability of exogenous trypsin to enhance SARS-CoV S-glycoprotein-mediated cell--cell fusion, but not infectivity by pseudotyped virion ([@bib50]). Reciprocally, cell--cell fusion by the MHV S glycoprotein is prevented by a peptidic furin inhibitor, whereas MHV infection is not ([@bib12]).

The recent finding that SARS-CoV entry is blocked by a specific inhibitor of the endosomal protease cathepsin L provides one plausible resolution to this conundrum ([@bib27], [@bib51]): the cleavage critical for viral entry may take place unobserved upon endocytosis or during vesicular trafficking. Other cleavage events mediated by furin, while evolutionarily conserved and no doubt important, may serve supportive or even distinct functions. A similar paradigm has been proposed for entry by the Ebola filovirus ([@bib10]). As in MHV, furin cleavage of the Ebola virus envelope glycoprotein precursor occurs in nature yet appears unnecessary for viral entry ([@bib43], [@bib61]).

Although further investigation of the role of endosomal proteases in viral entry will no doubt reveal additional detail to this novel mechanism for envelope glycoprotein activation, the function of the highly conserved furin cleavage site in the CoV life cycle remains unclear. In this regard, it is worthwhile to note another trait of the CoV S glycoproteins that is phylogenetically linked to the presence or absence of the furin cleavage site. In the ectodomain of S glycoproteins that remain uncleaved (group 1 CoVs), the N- and C-terminal heptad-repeat regions are extended by two additional in-register units (14 amino acids) relative to those of S glycoproteins that normally undergo furin cleavage (groups 2 and 3 CoVs). These heptad-repeat regions in Class I viral fusion proteins form the six α-helical core of the trimer-of-hairpins structure upon envelope glycoprotein activation and, in doing so, contribute energetically toward the initiation of membrane fusion (([@bib15], [@bib28], [@bib52], [@bib60]) and references therein). By this model, the extended heptad repeats in the group 1 viruses may facilitate formation of the six-helix bundle and membrane fusion, perhaps in compensation for the lack of furin cleavage. Biophysical and structural evidence for this suggestion is however lacking.

It is of interest, then, that the S glycoproteins of the SARS-CoV and its related CoVs ([@bib23], [@bib36], [@bib38]) represent an exception to this rule in the other CoVs. Despite the lack of furin cleavage, these glycoproteins contain only the shorter heptad-repeat regions. The consequences of this exception for viral replication, pathogenesis and CoV ecology are unknown. Further studies of CoV entry and the role of proteolytic cleavage events in this process are likely to impact our understanding of CoV pathogenesis and our ability to respond to newly emerging CoVs.

Materials and methods
=====================

Molecular reagents and monoclonal antibodies
--------------------------------------------

The S glycoprotein gene of the Urbani isolate of SARS-CoV ([@bib32]) was obtained from P. Rota (Centers for Disease Control and Prevention, Atlanta) and adapted for expression in pcDNA3.1^−^ (Invitrogen). We further modified this plasmid to introduce an S-peptide (Spep) affinity tag ([@bib29]) at the cytoplasmic C-terminus of the S glycoprotein to facilitate manipulations. The Spep addition is innocuous with regard to S-glycoprotein-mediated membrane fusion ([@bib16]), in keeping with reports of other C-terminal tags ([@bib4], [@bib8], [@bib41]). Mutations were introduced by using QuikChange mutagenesis (Stratagene) and confirmed by DNA sequencing. A plasmid encoding the cell surface receptor of the SARS-CoV, angiotensin-converting enzyme 2 (ACE2) was provided by M. Farzan (Harvard Medical School, Boston) ([@bib37]). Mouse monoclonal antibodies (MAbs) directed to the S glycoprotein were provided by J. Berry (National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg) ([@bib3], [@bib24]). The human furin precursor cDNA ([@bib9]) was from G. Thomas (Oregon Health Sciences University, Portland) and was transferred to pcDNA3.1^−^ for expression. Wild-type Chinese hamster ovary (CHO) cells and the furin-deficient derivative FD11 ([@bib22]) were provided by S. Leppla (National Institutes of Health, Bethesda).

Expression of the S glycoprotein
--------------------------------

The full-length S glycoprotein was transiently expressed using the pcDNA3.1^−^ T7 promoter and the recombinant vaccinia virus vTF7-3 encoding T7 polymerase ([@bib16], [@bib17]). vTF7-3 was obtained from T. Fuerst and B. Moss (National Institutes of Health) through the NIH AIDS Research and Reference Reagent Program. COS-7 cells were infected with the recombinant vaccinia virus at a multiplicity of eight in Dulbecco\'s Minimal Essential Medium (DMEM) containing 2% fetal bovine serum (FBS). Cytosine arabinoside (araC) was added to the medium at 10 μM to limit vaccinia virus expression ([@bib26]). CHO cells were infected at a multiplicity of eight in F12 medium containing 2% FBS. After 30 min, infected cells were washed and transfected with the S glycoprotein expression plasmid using FuGene-6 reagent (Roche Biochemicals). Metabolic labeling using 80 μCi/ml of \[^35^S\]-ProMix (Amersham Pharmacia Biotech) was initiated 6 h post-transfection in methionine- and cysteine-free DMEM containing 10% dialyzed FBS and 10 μM araC and was continued for 12--16 h. Cell culture supernatants were collected, cleared and filtered (0.2 μm) and were made to 1% Triton X-100 and 1 μg/ml each of protease inhibitors (aprotinin, leupeptin and pepstatin) prior to immunoprecipitation using the S1 domain-directed MAb F26G18 ([@bib3]) and Protein A--Sepharose (Sigma). Cells were washed in physiological buffered saline (PBS) and lysed using cold Tris--saline buffer (50 mM Tris--HCl and 150 mM NaCl at pH 7.5) containing 1% Triton X-100 nonionic detergent and protease inhibitors. A soluble fraction was prepared by centrifugation at 15,000 × *g* for 15 min at 4 °C. The S glycoproteins in cell lysates were isolated using the Spep affinity tag and S-protein agarose (Novagen). Comparable results were obtained by immunoprecipitation from cell lysates (not shown). In some studies, the glycoproteins were deglycosylated using peptide N-glycosidase (PNGase F; New England Biolabs). The isolated glycoproteins and deglycosylated polypeptides were resolved using NuPAGE 3--8% Tris--acetate gels (Invitrogen) and the recommended sample buffer containing lithium dodecyl sulfate and reducing agent. Molecular size markers are \[^14^C\]-methylated Rainbow proteins (Amersham Pharmacia Biotech). Radiolabeled proteins were imaged using a Fuji FLA-3000G imager and analyzed using ImageGauge software (Fuji).

Flow cytometry
--------------

COS-7 cells transiently expressing the SARS-CoV S glycoprotein were labeled using either the S1-directed MAb F26G18 ([@bib3]) and a secondary fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch) or with recombinant soluble ACE2 receptor (R&D Systems; 0.5 μg in 100 μl), biotinylated goat anti-ACE2 antibody (R&D Systems) and FITC-conjugated streptavidin (BD Biosciences). Cells were subsequently stained using propidium iodide (1 μg/ml) and then fixed in 2% formaldehyde. Populations were analyzed using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).

S-glycoprotein-mediated cell--cell fusion
-----------------------------------------

The β-galactosidase fusion reporter assay ([@bib44]) was used to assess the ability of the S glycoproteins to mediate receptor-dependent cell--cell fusion ([@bib16]). The recombinant vaccinia virus vCB21R-lacZ expressing β-galactosidase under the control of the T7 promoter ([@bib1]) was obtained from C. Broder, P. Kennedy and E. Berger (NIH) through the NIH AIDS Research and Reference Reagent Program. In these studies, cells infected with vTF7-3 and expressing the S glycoprotein were co-cultured with target COS-7 cells transfected to express the SARS-CoV cellular receptor ACE2 ([@bib37]) and infected with vCB21R-lacZ. Upon fusion of the effector and target cells, β-galactosidase expression was induced. To generate the target cell population, COS-7 cells that had been transfected 1 day previously with the ACE2 expression plasmid ([@bib37]) were incubated with vCB21R-lacZ at a multiplicity of 10 and the infection was allowed to proceed overnight in the presence of 100 μg/ml of the vaccinia virus assembly inhibitor rifampicin. The following day, S-glycoprotein-expressing cells and ACE2-expressing target cells were co-cultured for 10 h in medium containing both araC and rifampicin ([@bib26], [@bib66]). Cultures were then fixed for 5 min at 4 °C in cold PBS containing 2% formaldehyde and 0.2% glutaraldehyde, and β-galactosidase activity was detected using the chromogenic X-gal substrate ([@bib44]). The numbers of blue syncytia per 24-well microculture dish were determined microscopically.

Pseudotyped virions
-------------------

Lentiviral virions bearing the SARS-CoV S glycoprotein were generated using the HIV-1 proviral vector pNL4-3.Luc.R^−^E^−^ ([@bib11]) obtained through the NIH AIDS Research and Reference Reagent program from N. Landau (Salk Institute, La Jolla, CA). To eliminate the requirement for recombinant vaccinia virus vTF7-3 in these studies, a codon-optimized S glycoprotein gene (Urbani strain; co-S-C9; [@bib41]) was obtained from M. Farzan (Harvard Medical School, Boston). The S glycoprotein reading frame was subsequently modified to remove the C-terminal tag, to generate the HTVR mutation and to delete the C-terminal 19 amino acids. This latter Δ19 truncation increased the efficiency of pseudotyping ([@bib18], [@bib20], [@bib41]). A plasmid expressing the vesicular stomatitis virus (VSV) G glycoprotein was provided by J. Rose (Yale University) and served as a control in our studies.

Pseudotyped virions were generated by co-transfection of the pNL4-3.Luc.R^−^E^−^ and pcDNA3.1-based envelope glycoprotein-expressing plasmids at a 4:1 ratio in COS-7 cells. Supernatants were harvested after 2 days and filtered (0.45 μm produce pseudotyped virion stocks. In these experiments, transfection efficiencies in the cultures were gauged by expression of the pNL4-3.Luc.R^−^E^−^-encoded luciferase gene. Chemiluminescence was assayed using Luc-Screen System reagents (Applied Biosystems) and a Tropix TR717 microplate luminometer. Luciferase expression was comparable in transfected cultures expressing either the wild-type or HTVR co-S glycoprotein. Pseudotyped virion stocks were used fresh to infect human 293T cells that had previously been transfected to transiently express human ACE2. Infection was determined 2 days later by expression of the luciferase reporter.

Metabolically labeled pseudotyped virions were examined to characterize the relative efficiency of S glycoprotein incorporation. Transfected cultures were labeled for 24 h prior to harvest using 80 μCi/ml of \[^35^S\]-ProMix (Amersham Pharmacia Biotech), and supernatant virions were purified by ultracentrifugation through 20% sucrose. Pelleted particles were lysed and immunoprecipitated using MAb F26G18 as described above. HIV proteins were separately precipitated using anti-HIV immunoglobulin from infected individuals (HIVIG; [@bib46]).
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